期刊文献+

HPLC法测定卡巴拉汀贴剂中药物含量及其体外透皮释放量 被引量:1

HPLC determination of rivastigmine in patches and the skin permeation behavior of the transdermal delivery system in vitro
下载PDF
导出
摘要 建立了一种卡巴拉汀贴片含量及其体外透皮释放量的高效液相色谱(HPLC)测定法,并用离体豚鼠皮肤为透皮屏障,采用改进Franz扩散池,研究卡巴拉汀透皮贴剂体外透皮性能。结果表明,卡巴拉汀在9.69~116.32μg/mL浓度范围内线性关系良好,检测限为0.17μg/mL,精密度RSD为0.12%~0.47%,低、中、高3个浓度的平均回收率分别为98.79%、98.59%、99.88%;该贴剂体外透皮释放曲线符合零级方程(Q=kt),为Q=59.91t+6.02,r=0.9987。所建立的HPLC方法灵敏、准确、操作简便,可有效测定卡巴拉汀贴剂的含量及其体外透皮释放量。 The HPLC method has been employed for the determination of rivastigmine in rivastigmine patches, and the skin permeation behavior of the patches was studied in vitro using a modified Franz diffusion pool and excised guinea pig skins. The results showed that the linear range was 9.69 - 116. 32 μg/mL (r = 0. 9999) with a limit of detection (LOD) of 0. 17 μg/mL. The relative standard deviations (RSD) were 0.12% - 0.47%. In the low, medium and high concentration ranges, the average recoveries of rivastigmine were 98.79% , 98.59% , 99.88% respectively. The cumulative permeation curves for the rivastigmine transdermal delivery system (TDDS) were demonstrated to Obey a zero order equation ( Q = kt) , of the form Q = 59.91t + 6.02, r = 0. 9987. This method is simple, rapid, sensitive and accurate. It can be used to determine rivastigmine in a TDDS.
出处 《北京化工大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第1期35-38,共4页 Journal of Beijing University of Chemical Technology(Natural Science Edition)
关键词 HPLC 卡巴拉汀 透皮贴剂 体外透皮释放 HPLC rivastigmine patches transcutaneous permeation in vitro
  • 相关文献

参考文献10

二级参考文献45

  • 1张丽萍,张洪娟,王朝宇.穴位透皮吸收制剂聚胺酯贴敷剂脑栓通的研制[J].黑龙江中医药,1996,25(6):46-46. 被引量:22
  • 2李娅芳,邓英杰,刘书琴,缪硕宁,韩丽梅,张寒煦.透皮吸收制剂研究进展[J].中国药学杂志,1997,32(1):3-7. 被引量:35
  • 3潘旭初.月桂氮怠酮对■丙嗪透皮吸收作用的研究[J].中国药学杂志,1997,32(1):25-27. 被引量:9
  • 4颜耀东,王勋章,黄晓洁,吴晓光.均匀设计法对中药贴敷剂基质配方的研究[J].中国药学杂志,1997,32(3):145-147. 被引量:7
  • 5KARTHIK A,SUBRAMANIAN GS,SURULIVELRAJAN M ,et al. Fluorimetric determination of rivastigmine in rat plasma by a reverse phase-High performance liquid chromatographic method-Application to a pharmacokinetie study [J]. Arzneimittelforschung, 2008,58(5) :205 -210.
  • 6[1]Meiran N, Stuss DT, Guzman DA, et al. Diagnosis of dementia:Methods for interpretation of scores of 5 neuropsychological test.Arch Neurol, 1996,53 (10): 1043.
  • 7[2]Rosler M, Anand R, Cicin - Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer' s disease: international randomized controlled trial. BMJ, 1999,318 (7184) :633.
  • 8[3]Risse SC, Raskind MA, Nochlin D,et al. Neuropathological findings in patients with clinical diagnoses of probable Alzheimer's disease. Am J Psychiatry,1990,147(2) :168.
  • 9[4]Shadlen MF, Larson EB. What' s new in Alzheimer' s disease treatment:Reasons for optimism about future pharmacologic options. Postgrad Med,1999,105(1): 109.
  • 10[5]Maire JC,Wurtman RJ. Choline production from choline -containing phospholipids: a hypothetical role in Alzheimer' s disease and aging. Prog Neuropsychopharmacol Biol Psychiatry, 1984,8(4 -6) :637.

共引文献19

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部